Trial Profile
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Ordesekimab (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Amgen
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 The study has been completed in Netherlands.